News | Heart Valve Technology | March 01, 2019

Global Market for Transcatheter Treatments to Double in Next Five Years

Benefits of open-heart repair alternative are pumping strong growth

Global Market for Transcatheter Treatments to Double in Next Five Years

March 1, 2019 — When it comes to treatment options for a damaged heart valve, nothing is getting more attention than transcatheter treatments, a minimally invasive surgical procedure in which a replacement valve is inserted without requiring patients to undergo open heart surgery. The transcatheter treatment global market is expected to double in a few years according to a new BCC Research report, due to several factors. These include:  

  • An expanding geriatric population;
  • Higher prevalence of chronic diseases;
  • Increasing diagnoses of heart valve disease;
  • Adoption of transcatheter techniques; and
  • Positive reimbursement and other healthcare reforms.

The global market for transcatheter treatment was valued at roughly $4 billion in 2018 and is expected to reach approximately $8 billion in 2023 at a compound annual growth rate (CAGR) of 14.8 percent, according to the BCC Research report “Transcatheter Treatment: Procedures and Heart Valve Market.”

Top competitors in the industry include: Abbott Laboratories, Boston Scientific Corp., Medtronic, Vascular Innovations Co. Ltd., Valcare Inc. and others.

Highlights from the report include:

  • Market segment analysis. The market has shifted from open surgical repair to transcatheter procedures due to their various advantages. The transcatheter aortic valve segment leads the global market, followed by transcatheter mitral valve devices.
  • Market region analysis. The U.S. is expected to maintain dominance in the global market of transcatheter treatment devices, reaching $4.8 billion by 2023 and increasing at a CAGR of 15.5 percent.
  • Global market drivers. Transcatheter procedures are being increasingly accepted worldwide because they offer more comfort to high-risk patients and have advantages in terms of operative risk and patient recovery time compared with open surgical repair.

“Transcatheter treatment has created a great buzz,” said Ritu Thakur Dangi, the report’s author. “Transcatheter mitral valve repair and replacement is a relatively new and niche segment globally, but it is growing and has strong potential due to a robust product pipeline. Now that transcatheter aortic valves have been successfully launched, unmet needs in mitral valve repair represent a future growth opportunity.”

The report also explores some significant barriers to market growth, including:

  • High costs of transcatheter heart valves;
  • Lack of awareness about valvular disease;
  • Stringent regulatory approval procedures;
  • Lack of healthcare infrastructure in developing regions;
  • The need for lifelong surveillance of artificial valves;
  • Procedure-associated risks and complications; and
  • Device recalls.

For more information: www.bccresearch.com

Related Content

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Overlay Init